Leukemia (AML & MDS): Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine
and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid
Leukemia or High-Risk Myelodysplastic Syndrome
What are the good and bad effects of using different new treatment options (azacitidine
& nivolumab or azacitidine & midostaurin) to one of the current standard treatment
options (azacitidine alone) given for patients with AML or MDS who cannot tolerate
or do not want to get intensive chemotherapy?
Basic Study Information
Purpose:Location: Cancer Center
If you participate in this study you will randomly be assigned to one of the following
treatment groups; Group A: azacitidine alone, Group B: azacitidine and nivolumab,
or Group C: azacitidine and midostaurin. The cycles for all study groups will repeat
until your disease gets worse or you or your study doctor decide you should stop.
Each cycle is 28 days.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03092674?term=S1612&rank=2
Study Reference #: CLEU18002
Lead Researcher (Principal Investigator)
Lead Researcher: Kristen O'Dwyer
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Learn More About These Conditions
More information about Leukemia, Myeloid, Acute
Trial Not Found
The study you are looking for is not active at this time.
Return to Search